Levocom 250 mg/25 mg, 100 tablets — Made in Ukraine — Free Delivery

Product description

Levocom tablets are used for the following indications:

• Parkinson's disease;
• Parkinson's syndrome.

Compound

One tablet contains (active ingredients):

• levodopa - 250 mg;
• carbidopa - 25 mg.

Excipients: corn starch, pregelatinized starch, indigo carmine dye (E 132), magnesium stearate, microcrystalline cellulose.

Contraindications

• established hypersensitivity to any component of the preparation;
• simultaneous use of non-selective monoamine oxidase (MAO) inhibitors (the use of these preparations should be discontinued at least two weeks before the appointment of treatment with Levocom); the preparation can be used only with selective MAO-B inhibitors in the recommended doses (for example, with selegiline HCl);
• severe psychosis;
• severe hepatic and renal impairment;
• severe heart failure;
• severe cardiac arrhythmia;
• acute stroke;
• conditions in which adrenergic preparations are contraindicated (for example, pheochromocytoma, hyperthyroidism, Cushing's syndrome);
• suspicious undiagnosed skin lesions (dermatoses) or a history of melanoma;
• glaucoma.

Mode of application

"Levocom" is used by adults inside. The dosage regimen is set by the doctor individually, depending on the severity of the disease, concomitant pathology and the therapeutic effect for adult patients who have previously received preparation treatment. For optimal effect, it is better to take the preparation daily without taking a break in use.

Patients who do not take levodopa: for patients who begin treatment with Levocom, the initial dose is ½ tablet 1 or 2 times a day after meals. If necessary, increase the dose by gradually adding ½ tablet daily or every other day until the optimal therapeutic effect is obtained. The therapeutic response to the preparation is observed within one day, and sometimes after one dose. The full effective dose of the  preparation is achieved within 7 days compared to weeks and months of using levodopa alone.

Patients taking levodopa: Levodopa should be discontinued at least 12 hours (24 hours for slow release) prior to starting Levocom therapy. The dose of the preparation should contain approximately 20% of the previous daily dose of levodopa.

Initial dose: for patients who receive less than 1500 mg of levodopa per day, the initial daily dose should be 75-100 mg of carbidopa and 300-400 mg of levodopa (use the preparation  with a dosage in the ratio of carbidopa / levodopa 1: 4) 3-4 doses per day. Patients receiving more than 1500 mg of levodopa per day should start with one tablet 3-4 times per day.

Supportive therapy: therapy with the combined preparation "Levocom" should take into account the individual characteristics of patients, the dosage can be gradually changed depending on the therapeutic effect.

In the case when a larger amount of levodopa is needed, the dose can be increased by ½ or one tablet each next day to a maximum daily dose of 200 mg of carbidopa and 2 g of levodopa (8 tablets in 3-4 divided doses) for patients weighing 70 kg.

When the transfer of a patient from levodopa to Levocom is combined with other decarboxylase inhibitors, their use should be discontinued at least 12 hours before starting Levocom.

For patients taking other antiparkinsonian preparations  simultaneously with Levocom, it may be necessary to adjust the dose of these preparations.

The combination of the preparation with MAO inhibitors type B (MAO-B) can increase the effectiveness of the preparation in controlled cases of akinesia and / or dyskinesia.

Application features

Pregnant

The effect on the course of pregnancy is unknown, however, both levodopa and its combination with carbidopa caused malformations of the internal organs and the skeleton of the fetus in an experiment on animals. Therefore, you should not use the preparation during pregnancy.

If it is necessary to use the preparation during lactation, it is necessary to stop breastfeeding for the period of treatment.

Children

The safety and efficacy of the preparation in children have not been established, so it should not be used in patients under the age of 18.

Drivers

Considering that when using the preparation, side reactions (dizziness, hallucinations, uncontrolled movements, drowsiness, cases of sudden sleep, visual disturbances) may occur, while taking the preparation, you should refrain from driving and performing other work requiring concentration.

Overdose

Precautions for overdose with Levocom are the same as for levodopa overdose, but pyridoxine is not effective in reducing the effect of Levocom.

Symptoms: involuntary movements, blepharospasm, arterial hypertension, increased heart rate, heart rhythm disturbances, confusion, agitation, insomnia, anxiety.

Treatment: artificially induce vomiting, urgently flush the stomach.

Symptomatic therapy: administer infusion with caution, pay attention to airway patency; when arrhythmia occurs, apply appropriate treatment with ECG monitoring. The value of dialysis for the treatment of overdose events has not been studied.

Side effects

When using levodopa / carbidopa, side effects are most often caused by the central neuropharmacological activity of dopamine: dyskinesias, dystonic and other involuntary movements, nausea. Muscle twitching and blepharospasm may be early signs for dose reduction. They disappear when the dose of the preparation is reduced or during treatment.

Storage conditions

Store in its original packaging at a temperature not exceeding 25 ° C, out of the reach of children.

Shelf life is 3 years.